MedTrace Logo

Abatacept in Patients With Birdshot HLA A29 Uveitis

NCT03871361 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-12-04

No results posted yet for this study

Summary

To assess the efficacy and safety of Abatacept as an immunosuppressive treatment in Birdshot uveitis. The primary objective is to test the efficacy to suppress inflammation in active Birdshot uveitis patients, using quantitative and qualitative measurements of visual function.

Conditions

  • Eye Diseases
  • Uveitis

Interventions

DRUG

Abatacept 125 MG/ML Prefilled Syringe

Abatacept 125 MG/ML Prefilled Syringe \[Orencia\] weekly

Sponsors & Collaborators

  • Ziekenhuis Netwerk Antwerpen (ZNA)

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Pieter-Paul FA Schauwvlieghe, MD · Universitaire Ziekenhuizen KU Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-01-01
Completion
2023-12-01

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03871361 on ClinicalTrials.gov